EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Outcomes and Prognostic Factors in Driver-Negative Stage IV Non-small Cell Lung Cancer Patients Receiving Thoracic Radiotherapy: A Single-Center Retrospective Study

Klinische Outcomes und prognostische Faktoren bei driver-negativem Stadium-IV-Nicht-kleinzelligem Lungenkarzinom unter thorakaler Radiotherapie: retrospektive Einzelzentrumsstudie

Chaozhen Shang iD, Jiangping Yang, Miao Wang, Na Peng, Bo Yang, Guoxu Wang, Haoyu Li, Simeng Tan, Qiao Fang, Mei Yang, Yaoxiong Xia

Technology in Cancer Research & Treatment · 2026-08 · 25

DOI: 10.1177/15330338261502238 ↗

Auf einen Blick

Bei 48 Patient:innen mit Stadium-IV-NSCLC ohne targetable Driver-Alterationen waren nach thorakaler Radiotherapie meist partielle Remission oder stabile Erkrankung zu sehen. Die prognostischen Befunde waren explorativ.

Fragestellung

Welche Outcomes, prognostische Faktoren und Sicherheitsdaten zeigen sich bei driver-negativem Stadium-IV-NSCLC unter thorakaler Radiotherapie plus Systemtherapie?

Methode

Retrospektive Kohortenstudie in einem Zentrum; Analyse von Patient:innen mit TRT und Systemtherapie von Januar 2019 bis Dezember 2023; Kaplan-Meier, Cox-Regression, Firth-Analyse und Landmark-Analysen.

Ergebnisse

48 Patient:innen. Medianes OS 33,17 Monate (95 %-KI 19,29–47,05), PFS 12,17 Monate (95 %-KI 8,89–15,45), LC 12,47 Monate (95 %-KI 9,00–15,98). Bestes In-Field-Ansprechen: 25,0 % PR, 66,7 % SD, 8,3 % PD.

Einschränkungen

Einzelzentrische retrospektive Studie; prognostische Analysen explorativ; kleinere Stichprobe; mögliche Zeitverzerrung wurde nur explorativ geprüft.

Schlussfolgerung der Autor:innen

Die meisten bestrahlten thorakalen Läsionen zeigten beim besten post-TRT-Befund eine partielle Remission oder stabile Erkrankung; bei Verstorbenen überwog die Fernprogression. Die prognostischen Befunde brauchen Validierung.

Kernaussagen

  • Medianes OS: 33,17 Monate; PFS: 12,17 Monate; LC: 12,47 Monate
  • Bestes In-Field-Ansprechen meist PR oder SD
  • Grad-3/4-Pneumonitis und -Ösophagitis jeweils bei 1 Patient:in

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 03.11.2026. Verfasst von Chaozhen Shang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospi…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yunnan Provincial Clinical Research Center Project, Medical Academic Leader Program of Yunnan Provincial Health Commission.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The role of thoracic radiotherapy (TRT) in stage IV non-small cell lung cancer (NSCLC) without targetable driver alterations remains unclear. We evaluated outcomes, prognostic factors, and safety in patients receiving TRT and systemic therapy.

Methods

In this single-center retrospective cohort study, we analyzed patients identified according to predefined criteria who received TRT and systemic therapy at a single tertiary cancer center between January 2019 and December 2023. Overall survival (OS), progression-free survival (PFS), and local control (LC) were estimated using Kaplan–Meier analysis. Conventional Cox regression constituted the primary prognostic analysis, with Firth penalized Cox regression used as a small-sample sensitivity analysis. Exploratory conditional landmark and time-dependent Cox analyses assessed potential time-related bias.

Results

Forty-eight patients were included. Median OS, PFS, and LC were 33.17 months (95% CI 19.29–47.05), 12.17 months (95% CI 8.89–15.45), and 12.47 months (95% CI 9.00–15.98), respectively. Best in-field response was partial response in 12 patients (25.0%), stable disease in 32 (66.7%), and progressive disease in 4 (8.3%). Squamous histology was consistently associated with poorer OS and PFS, whereas other multivariable associations were less stable in sensitivity analyses. Time-dependent anti-PD-1 exposure was not significantly associated with OS. Metastatic progression predominated among patients who died. In the exploratory 6-month conditional landmark analysis, TRT timing was not associated with OS or PFS. Grade 3–4 pneumonitis and esophagitis each occurred in one patient (2.1%), and no grade 5 adverse event was documented.

Conclusion

Most irradiated thoracic lesions showed partial response or stable disease at the best post-TRT assessment, while distant progression predominated among patients who died during follow-up. The prognostic findings are exploratory and require validation in larger prospective cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansFemaleRetrospective StudiesPrognosisMaleNeoplasm StagingAgedMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

Immortal time biasImmune checkpoint inhibitorsNon-small cell lung cancerStage IV diseaseThoracic radiotherapy

Autor:innen und Institutionen

  • Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.
  • Graduate School, Kunming Medical University, Kunming, Yunnan, China.
  • Department of Oncology, Qujing Central Hospital of Yunnan Province, Qujing, Yunnan, China.
  • Phase I Clinical Trial Ward, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, Yunnan, China.

ORCID-Profile: Chaozhen Shang

Förderung

  • Yunnan Provincial Clinical Research Center Project
  • Medical Academic Leader Program of Yunnan Provincial Health Commission

Zitieren

APA

Shang, C., Yang, J., Wang, M., Peng, N., Yang, B., Wang, G., Li, H., Tan, S., Fang, Q., Yang, M., & Xia, Y. (2026). Clinical Outcomes and Prognostic Factors in Driver-Negative Stage IV Non-small Cell Lung Cancer Patients Receiving Thoracic Radiotherapy: A Single-Center Retrospective Study. Technology in Cancer Research & Treatment, 25. https://doi.org/10.1177/15330338261502238

Vancouver

Shang C, Yang J, Wang M, Peng N, Yang B, Wang G, et al. Clinical Outcomes and Prognostic Factors in Driver-Negative Stage IV Non-small Cell Lung Cancer Patients Receiving Thoracic Radiotherapy: A Single-Center Retrospective Study. Technology in Cancer Research & Treatment. 2026;25. doi:10.1177/15330338261502238

BibTeX
@article{Shang2026,
  author = {Shang, Chaozhen and Yang, Jiangping and Wang, Miao and Peng, Na and Yang, Bo and Wang, Guoxu and Li, Haoyu and Tan, Simeng and Fang, Qiao and Yang, Mei and Xia, Yaoxiong},
  title = {Clinical Outcomes and Prognostic Factors in Driver-Negative Stage IV Non-small Cell Lung Cancer Patients Receiving Thoracic Radiotherapy: A Single-Center Retrospective Study},
  journal = {Technology in Cancer Research & Treatment},
  year = {2026},
  volume = {25},
  doi = {10.1177/15330338261502238}
}
Kostenlos starten →